0S90 Stock Overview A biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. More details
Rewards Risk Analysis + 5 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Syros Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Syros Pharmaceuticals Historical stock prices Current Share Price US$0.15 52 Week High US$7.44 52 Week Low US$0.15 Beta 1.29 1 Month Change -36.67% 3 Month Change -91.01% 1 Year Change -97.67% 3 Year Change -99.50% 5 Year Change -99.75% Change since IPO -99.80%
Recent News & Updates
New major risk - Revenue and earnings growth Nov 14
Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression Nov 13
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) Nov 01
Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 25
Chief Financial Officer recently bought €146k worth of stock Sep 13
New minor risk - Profitability Aug 13 See more updates
New major risk - Revenue and earnings growth Nov 14
Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression Nov 13
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) Nov 01
Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 25
Chief Financial Officer recently bought €146k worth of stock Sep 13
New minor risk - Profitability Aug 13
Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial Aug 13
First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023) Aug 01
Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 24
New minor risk - Profitability May 16
First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023) May 15
Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024 May 09
Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024 Apr 24
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression Apr 09
New minor risk - Profitability Mar 28
No longer forecast to breakeven Mar 28
Full year 2023 earnings released: US$5.81 loss per share (vs US$7.49 loss in FY 2022) Mar 28
Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 21
Forecast to breakeven in 2026 Dec 31 Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million. Dec 21
Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million. Dec 19
Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine Dec 06
Third quarter 2023 earnings released: US$1.43 loss per share (vs US$3.21 loss in 3Q 2022) Nov 16
New major risk - Revenue and earnings growth Nov 16
Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023 Oct 05
New major risk - Share price stability Oct 05
Second quarter 2023 earnings released: US$1.30 loss per share (vs US$5.40 loss in 2Q 2022) Aug 09
Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting May 26
First quarter 2023 earnings released: US$0.85 loss per share (vs US$3.99 loss in 1Q 2022) May 11
Full year 2022 earnings released: US$7.49 loss per share (vs US$13.84 loss in FY 2021) Mar 03
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Jan 28
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds Dec 13
Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial Dec 11
Third quarter 2022 earnings released: US$3.21 loss per share (vs US$4.14 loss in 3Q 2021) Nov 17
Insufficient new directors Nov 17
Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 08
Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement Oct 07
Insider recently bought €108k worth of stock Oct 04 Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.
Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.36 loss in 2Q 2021) Aug 10
Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS Aug 04
Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 03 Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million. Jul 07
Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.
First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.23 loss in 1Q 2021) May 17 Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022 May 10
Insufficient new directors Apr 27
Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022 Apr 22
Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022 Apr 10
Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022 Apr 09
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 16
Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones Jan 12
Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.43 loss in 3Q 2020) Nov 06
Syros Pharmaceuticals, Inc. Presents New Data from Phase 1 Trial of Sy-5609 and Details Three-Pronged Combination Strategy to Advance Sy-5609 in Solid Tumors and Blood Cancer Sep 21
Syros Pharmaceuticals Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML Sep 10
Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.38 loss in 2Q 2020) Aug 06
Forecast to breakeven in 2025 May 15
First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.39 loss in 1Q 2020) May 06
New 90-day low: €6.60 Mar 06
Full year 2020 earnings released: US$1.83 loss per share (vs US$1.88 loss in FY 2019) Mar 05
Revenue beats expectations Mar 05
Syros Pharmaceuticals, Inc. announced that it has received $20 million in funding from Oxford Finance LLC Dec 24
New 90-day high: €8.75 Dec 10
Syros Pharmaceuticals, Inc. Announces the New Clinical Data from its Phase 2 Trial Evaluating SY-1425 Dec 06
Revenue beats expectations Nov 07
Third quarter 2020 earnings released: US$0.43 loss per share Nov 07
Syros Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Nov 01
New 90-day low: €6.50 Oct 21
New 90-day low: €6.95 Oct 05
New 90-day low - €7.55 Sep 10
New 90-day high - €11.80 Aug 20
Syros Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Jul 31 Shareholder Returns 0S90 DE Biotechs DE Market 7D -4.4% -0.8% -1.6% 1Y -97.7% -13.0% 6.8%
See full shareholder returns
Return vs Market: 0S90 underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is 0S90's price volatile compared to industry and market? 0S90 volatility 0S90 Average Weekly Movement 35.1% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0S90's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0S90's weekly volatility has increased from 22% to 35% over the past year.
About the Company Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.
Show more Syros Pharmaceuticals, Inc. Fundamentals Summary How do Syros Pharmaceuticals's earnings and revenue compare to its market cap? 0S90 fundamental statistics Market cap €5.24m Earnings (TTM ) -€94.09m Revenue (TTM ) €371.29k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0S90 income statement (TTM ) Revenue US$386.00k Cost of Revenue US$88.64m Gross Profit -US$88.25m Other Expenses US$9.56m Earnings -US$97.81m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.65 Gross Margin -22,862.95% Net Profit Margin -25,340.67% Debt/Equity Ratio -369.3%
How did 0S90 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 04:22 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Syros Pharmaceuticals, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Leah Rush Cann Brookline Capital Markets Andrew Fein H.C. Wainwright & Co. Jason Butler JMP Securities
Show 6 more analysts 
